Hemophilia B Etranacogene dezaparvovec, the first gene therapy for treating hemophilia B, a genetic bleeding disorder resulting from missing or insufficient levels of factor IX, was approved by ...

Preventive treatment with Pfizer's Hympavzi can reduce bleeding rates in hemophilia A or B patients with inhibitors, new ...

In hemophilia patients, it is very risky to perform spinal anesthesia, since a hemorrhage in the spine could cause irreversible neurological damage. For this reason, ...

The Thursday regulatory decision for the gene therapy, Roctavian, covers adults with severe hemophilia A. BioMarin set a $2.9 million wholesale price for the product.

The New York drugmaker on Wednesday said the approval covers Hympavzi for the routine preventions of bleeding episodes in patients 12 and older with severe hemophilia A or B without inhibitors.

In hemophilia patients, it is very risky to perform spinal anesthesia, since a hemorrhage in the spine could cause irreversible neurological damage. For this reason, ...